Tiziana Life Sciences announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer’s Disease in Q2 2023. "Following the FDA feedback from our protocol and development plans from the August 2022 type "B" Pre-IND meeting, Tiziana plans submit its intranasal foralumab protocol and IND for mild to moderate Alzheimer’s disease in Q2 2023," stated Gabriele Cerrone, Executive Chairman, Founder and interim Chief Executive Officer of Tiziana. "Tiziana is also seeking $3,000,000 in non-dilutive funding from a prestigious Alzheimer’s foundation to support the Phase 2a trial. It is my expectation that this funding application will be submitted Q2 2023 with a response expected Q3 2023."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TLSA:
- Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
- Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
- Tiziana Life Sciences initiates program to develop foralumab in T1D
- Tiziana to develop intranasal foralumab for the treatment of long COVID
- Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai